The Treatment of Adult Acute Myelogenous Leukemia with AD Induction Therapy Followed by Consolidation Therapy with Intermediate Dose Ara-C; Long Term Follow-up Results.
- Author:
Dae Ho LEE
1
;
Soo Mee BANG
;
Joo Young JUNG
;
Jin Seok AHN
;
Chul Won JUNG
;
Kyung Hae JUNG
;
Sung Soo YOON
;
Myung Don OH
;
Seonyang PARK
;
Byoung Kook KIM
;
Kang Won CHOE
;
Han Ik CHO
;
Noe Kyeong KIM
Author Information
1. Department of Internal medicine, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Adult acute myelogenous leukemia;
Intermediate dose of Ara-C;
Consolidation therapy
- MeSH:
Adult*;
Bone Marrow Transplantation;
Cardiomyopathies;
Consolidation Chemotherapy;
Cytarabine*;
Daunorubicin;
Disease-Free Survival;
Follow-Up Studies*;
Humans;
Induction Chemotherapy;
Informed Consent;
Leukemia, Myeloid, Acute*;
Mortality;
Retrospective Studies;
Seoul;
Siblings;
Tissue Donors
- From:Korean Journal of Hematology
2002;37(2):97-105
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study was to evaluate the therapeutic efficacy of consolidation therapy based on intermediate dose Ara-C in patients with newly diagnosed acute myelogenous leukemia (AML) in Seoul National University Hospital. And also, this study was to assess the toxicities of the treatment. METHODS: We have reviewed retrospectively our experience of patients with newly diagnosed non-M3 AML between January 1993 and July 1997. They were treated with induction chemotherapy with Ara-C 200mg/m2/d over 24 h for 7 days and daunorubicin 45mg/m2/d daily for 3 days. The patients achieving complete remission (CR) are to receive the 3 courses of consolidation chemotherapy based on intermediate dose of Ara-C 1,000mg/m2 given over 2h every 12 h for a total of eight to ten doses. Patients having HLA-matched sibling donors with informed consent could receive allogeneic bone marrow transplantation (BMT). RESULTS: One hundred and fifteen patients were reviewed. The median age was 41 years (range, 16-69) and median follow-up was 75 months. The CR rate was 72.2%. The median disease-free survival (DFS) of patients receiving consolidation therapy and allogeneic BMT was 21 months and 26.5 months, respectively. The overall survival (OS) was 13 months for patients not-receiving consolidation therapy, 21 months for consolidation therapy, and 31 months for allogeneic BMT, respectively. The rate of treatment-related mortality of consolidation therapy was 14% and cause of all deaths was infection. But in allogeneic BMT, that mortality rate was 42%; 2 infections, 2 veno-occlusive diseases and 1 cyclophosphamide-induced cardiomyopathy. CONCLUSION: Patients receiving consolidation therapy with intermediate dose Ara-C had longer DFS and OS. But their DFS and OS was not superior to that of patients receiving allogeneic BMT. In addition, that result was inferior to that of patients receiving high dose Ara-C based consolidation therapy, compared with other previous studies. However, this study was retrospective and so further prospective study will be required for comparing different doses of Ara-C consolidation therapy versus BMT.
